Patents Assigned to ReNeuron Limited
-
Patent number: 10406182Abstract: This invention relates to stem cell microparticles and miRNA isolated from these microparticles, their use and production thereof, in particular neural stem cell microparticles and their use in therapy of cancer, typically a nestin-positive cancer. The cancer may be glioma, melanoma, breast cancer, pancreatic cancer or prostate cancer. The stem cell microparticle is typically an exosome or microvesicle and may be derived from a neural stem cell line. The neural stem cell line may be a conditionally-immortalized stem cell line such as CTX0E03 (deposited at the ECACC with Accession No. 04091601).Type: GrantFiled: October 9, 2014Date of Patent: September 10, 2019Assignee: Reneuron LimitedInventors: Caroline Hicks, John Sinden, Lara Stevanato, Randolph Corteling
-
Patent number: 9629879Abstract: The present invention provides an isolated cell obtainable from the CTX0E03 neural stem cell line for use in the treatment of a disorder associated with elevated levels of pro-inflammatory cytokines, wherein the disorder is selected from unipolar and bipolar depression, schizophrenia, obsessive compulsive disorder, autism and autistic syndrome disorders.Type: GrantFiled: July 11, 2011Date of Patent: April 25, 2017Assignee: RENEURON LIMITEDInventors: Randolph Corteling, Caroline Hicks, John Sinden, Jack Price
-
Patent number: 9410122Abstract: The present invention uses neural stem cells in the manufacture of a medicament for the treatment of a patient suffering peripheral arterial disease. The invention is particularly suited for treating limb ischemia or Buerger's disease.Type: GrantFiled: August 4, 2014Date of Patent: August 9, 2016Assignee: RENEURON LIMITEDInventors: John Sinden, Erik Miljan, Paolo Madeddu
-
Patent number: 9265795Abstract: The present invention provides a therapeutic composition comprising: (i) Trolox, Na+, K+, Ca2+, Mg2+, Cl?, H2PO4?, HEPES, lactobionate, sucrose, mannitol, glucose, dextran-40, adenosine, glutathione; and (ii) stem cells or progenitor cells, wherein the composition does not comprise a dipolar aprotic solvent, in particular DMSO. The present invention also relates to methods of formulating said composition for cryopreservation and subsequent direct administration to a patient, and medicaments comprising said composition.Type: GrantFiled: December 7, 2009Date of Patent: February 23, 2016Assignee: RENEURON LIMITEDInventors: Andrew Hope, Erik Miljan, John Sinden
-
Patent number: 8932577Abstract: The present invention uses neural stem cells in the manufacture of a medicament for the treatment of a patient suffering peripheral arterial disease. The invention is particularly suited for treating limb ischemia or Buerger's disease.Type: GrantFiled: February 5, 2010Date of Patent: January 13, 2015Assignee: Reneuron LimitedInventors: John Sinden, Erik Miljan, Paolo Madeddu
-
Publication number: 20130171177Abstract: The present invention provides an isolated cell obtainable from the CTX0E03 neural stem cell line for use in the treatment of a disorder associated with elevated levels of pro-inflammatory cytokines, wherein the disorder is selected from unipolar and bipolar depression, schizophrenia, obsessive compulsive disorder, autism and autistic syndrome disorders.Type: ApplicationFiled: July 11, 2011Publication date: July 4, 2013Applicant: RENEURON LIMITEDInventors: Randolph Corteling, Caroline Hicks, John Sinden, Jack Price
-
Publication number: 20130045189Abstract: The subject invention pertains to methods to enhance the therapeutic effects of cellular or drug treatment in various diseases and disorders. More particularly, the present invention provides methods of treating disorders by administering CTX0E03 cells to the patient, intravenously or intraarterially. The treatment is useful for neurodegenerative diseases, such as stroke. The CTX0E03 cells may be cryopreserved and/or passaged before administration into the patient. Administration of the CTX0E03 cells into stroke rat models was at or within 48 hours after stroke. Testing of the rat models through elevated body swing test to measure of neurobehavioral status at the time of transplant and repeated triphenyltetrazolium chloride (TTC) staining as a measure of infarct volume showed short term survival that provided significant protection from the stroke.Type: ApplicationFiled: October 25, 2012Publication date: February 21, 2013Applicants: RENEURON LIMITED, UNIVERSITY OF SOUTH FLORIDAInventors: UNIVERSITY OF SOUTH FLORIDA, RENEURON LIMITED
-
Publication number: 20120093786Abstract: The present invention uses neural stem cells in the manufacture of a medicament for the treatment of a patient suffering peripheral arterial disease. The invention is particularly suited for treating limb ischemia or Buerger's disease.Type: ApplicationFiled: February 5, 2010Publication date: April 19, 2012Applicant: RENEURON LIMITEDInventors: John Sinden, Erik Miljan, Paolo Madeddu
-
Publication number: 20120076854Abstract: The present invention provides a therapeutic composition comprising: (i) Trolox, Na+, K+, Ca2+, Mg2+, Cl?, H2PO4?, HEPES, lactobionate, sucrose, mannitol, glucose, dextran-40, adenosine, glutathione; and (ii) stem cells or progenitor cells, wherein the composition does not comprise a dipolar aprotic solvent, in particular DMSO. The present invention also relates to methods of formulating said composition for cryopreservation and subsequent direct administration to a patient, and medicaments comprising said composition.Type: ApplicationFiled: December 7, 2009Publication date: March 29, 2012Applicant: Reneuron LimitedInventors: Andrew Hope, Erik Miljan, John Sinden
-
Patent number: 7666672Abstract: The present invention relates to cells obtainable from cell lines having the ECACC Accession Nos 04091601, 04110301 and 04092302.Type: GrantFiled: January 28, 2008Date of Patent: February 23, 2010Assignee: Reneuron LimitedInventors: John Sinden, Kenneth Pollock, Paul Stroemer
-
Patent number: 7419827Abstract: Genomic instability in T-antigen expressing cells can be overcome by modifying the gene expressing T-antigen so that it lacks Bub1 binding. Stable cell lines can be produced by incorporation of the modified T-antigen gene, preferably together with the catalytic sub-unit of the telomerase construct.Type: GrantFiled: November 21, 2005Date of Patent: September 2, 2008Assignee: Reneuron LimitedInventors: John Sinden, Kenneth Pollock, Paul Stroemer
-
Patent number: 7416888Abstract: The present invention relates to cells obtainable from cell lines having the ECACC Accession Nos 04091601, 04110301 and 04092302.Type: GrantFiled: September 29, 2005Date of Patent: August 26, 2008Assignee: Reneuron LimitedInventors: John Sinden, Kenneth Pollock, Paul Stroemer
-
Patent number: 7371374Abstract: The subject invention pertains to a novel method of correction of behavioral and/or psychological deficits made possible by the intracerebral transplantation of pluripotent neuroepithelial cells. Cells, cell lines, pharmaceutical preparations, medicaments, methods for the production and maintenance of the cell lines for use in the method of the invention are encompassed by the invention.Type: GrantFiled: July 8, 2005Date of Patent: May 13, 2008Assignee: ReNeuron LimitedInventors: John Sinden, Jeffrey A. Gray, Helen Hodges, Timothy Kershaw, Fiza Rashid-Doubell
-
Patent number: 7247298Abstract: The present invention relates to the treatment of brain damage by cellular transplantation. According to one aspect of the invention, a method for treating a motor, sensory and/or cognitive deficit comprises administering a composition comprising pluripotent cells into the damaged brain in a region contra-lateral to that containing the site of damage. The cells are preferably conditionally immortal.Type: GrantFiled: January 14, 2003Date of Patent: July 24, 2007Assignee: ReNeuron LimitedInventor: Helen Hodges
-
Patent number: 7048921Abstract: The subject invention pertains to a novel method of correction of behavioral and/or psychological deficits made possible by the intracerebral transplantation of pluripotent neuroepithelial cells. Cells, cell lines, pharmaceutical preparations, medicaments, methods for the production and maintenance of the cell lines for use in the method of the invention are encompassed by the invention.Type: GrantFiled: January 12, 2001Date of Patent: May 23, 2006Assignee: ReNeuron LimitedInventors: John Sinden, Jeffrey A. Gray, Helen Hodges, Timothy Kershaw, Fiza Rashid-Doubell
-
Patent number: 6569421Abstract: The present invention relates to the treatment of brain damage by cellular transplantation. According to one aspect of the invention, a method for treating a motor, sensory and/or cognitive deficit comprises administering a composition comprising pluripotent cells into the damaged brain in a region contra-lateral to that containing the site of damage. The cells are preferably conditionally immortal.Type: GrantFiled: March 29, 2000Date of Patent: May 27, 2003Assignee: Reneuron LimitedInventor: Helen Hodges
-
Patent number: 6465215Abstract: Pluripotent cells that are suitable for transplantation therapy, to repair neural damage, are identified, e.g. by differential display, from a gene expression profile for a selected cell, which can be compared with that obtained from a control cell.Type: GrantFiled: October 25, 2000Date of Patent: October 15, 2002Assignee: Reneuron LimitedInventors: Jack Price, Dafe Uwanogho
-
Patent number: 6399384Abstract: A recombinant, or genetically engineered, mammalian cell, comprises a conditionally-inducible oncogene and an exogenous polynucleotide encoding the catalytic sub-unit of the telomerase complex. The recombinant cells are useful in therapy, to replace lost or damaged cells.Type: GrantFiled: September 15, 2000Date of Patent: June 4, 2002Assignees: Reneuron Limited, Ludwig Institute for Cancer ResearchInventor: Parmjit Jat